A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- OBSERVATIONAL
- Evidence population
- Human clinical study registration
- Participants
- 30
- Population
- ALL · 50 Years
- Duration
- 2022-07-11 to 2025-12-31
- Intervention
- Comparator
- Not reported
- Outcomes measured
- changes in blue autofluorescence using Spectral Domain Optical Coherence Tomography (SD-OCT) — form baseline to month 6; The change in SrAF To evaluate the modification of SrAF stimulated by the PBM treatment — from baseline until month 6; Evaluation of changes in Best Corrected Visual Acuity (ETDRS) — form baseline to month 6; Evaluation of changes in contrast sensitivity — form baseline to month 6; evaluation of drusen volume, central drusen thickness, retinal volume, and central retinal thickness using Spectral Dom…; evaluation of changes in choriocapillary perfusion density on Swept Source Optical Coherence Tomography Angiography (SS…; evaluation of changes in retinal sensitivity on microperimetry and the rate of progression to advanced AMD (geographic…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.
